OIG - Office of Inspector General
07/20/2026 | Press release | Archived content
EyePoint Pharmaceuticals to Pay $4.6 Million to Resolve False Claims Act Allegations
EyePoint Pharmaceuticals to Pay $4.6 Million to Resolve False Claims Act Allegations
Eyepoint Pharmaceuticals, Inc., (EyePoint) headquartered in Massachusetts, has agreed to pay the United States $ 4,657,463.18 to resolve allegations that it violated the False Claims Act by paying kickbacks to certain Ambulatory Service Centers (ASCs) to induce those ASCs to purchase and dispense DEXYCU, an injectable drug approved for the treatment of ocular inflammation following cataract surgery, between January 1, 2019 and March 1, 2023.
More About This Action
Action Details
- Date:July 20, 2026
- Agency:U.S. Department of Justice
-
Enforcement Types:
- Criminal and Civil Actions
OIG - Office of Inspector General published this content on July 20, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 22, 2026 at 18:08 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]